Ipsen: North American Head Departs, Former Novartis Executive to Take Over
Ipsen announces the appointment of Michelle C. Werner as the new Executive Vice President (EVP) and President of North America, effective March 23, 2026. She will join the Executive Leadership Team (ELT) and report directly to CEO David Loew.
Michelle C. Werner comes to Ipsen from Alltrna, where she has served as President and CEO since 2022. She brings over 25 years of experience in the pharmaceutical industry. Her career includes roles at Bristol Myers Squibb (BMS), such as Director of Global Market Access Strategy for oncology and virology portfolios (2009), Global Brand Lead for the non-small cell lung carcinoma portfolio (2011), and U.S. Brand Lead for Reyataz® and Evotaz® franchises (2014). She also held positions as the Head of the Immuno-Oncology Franchise and Oncology Business Unit in the US at AstraZeneca (2015), President for the Nordic and Baltic countries based in Sweden (2018), and Global Franchise Head of Hematology (2020). Before joining Alltrna, she was the Global Franchise Head of Solid Tumors at Novartis Oncology starting in July 2020.
Leadership Transition
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Keira Driansky, the former Executive Vice President and President of North America, is leaving the company to pursue external opportunities. During her two-year tenure at Ipsen, Keira Driansky led a significant transformation of the American subsidiary, contributing to increased sales in the United States and enhancing Ipsen's brand visibility in the American market.
"En 2025, Ipsen a enregistré une croissance solide de son chiffre d'affaires et de son résultat opérationnel."
Ipsen a publié ses résultats 2025 et T4 2025: chiffre d'affaires de 3 675,9 millions d'euros, croissance YoY de 8,1%; Résultat opérationnel des activités de 1 294,1 millions d'euros, marge de 35,2%; Résultat net consolidé IFRS de 444,5 millions d'euros; Bénéfice dilué par action IFRS de 5,32 euros; Cash-flow libre de 1 000,6 millions d'euros; Dividende par action de 1,40 euro.
Outlook / guidance
Expected revenue: Une croissance des ventes totales supérieure à 13,0 % à taux de change constant en 2026
Management commentary: Ipsen prévoit en 2026 une croissance des ventes totales supérieure à 13,0% à taux de change constant et une marge opérationnelle des activités supérieure à 35,0%.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
